CIBC Keeps Sector Outperform On Protein Design Labs

Analyst Matt Geller says the biotech's ESP Pharma acquisition is a major positive for both short-term and long-term growth

CIBC keeps sector outperform on Protein Design Labs (PDLI ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.